 SAN DIEGO, Nov. 02, 2021 GLOBE NEWSWIRE -- Travere Therapeutics, Inc. NASDAQ: TVTX today announced that the Company and its collaborators will present abstracts based on non-clinical data describing the potential for sparsentan, an investigational product candidate, to protect kidney function in models of rare glomerular diseases, including a potential anti-inflammatory role in IgA nephropathy IgAN, at the American Society of Nephrology ASN Kidney Week 2021. Sparsentan is a Dual Endothelin Angiotensin Receptor Antagonist DEARA currently in Phase 3 clinical development for the treatment of IgAN and focal segmental glomerulosclerosis FSGS. The company will also present data from natural history studies highlighting the challenges associated with managing IgAN and FSGS, as well as data indicating poor renal survival in children and adults living with these rare kidney disorders. In addition, an analysis of the association between achieving complete or partial remission of proteinuria and delaying the progression to end-stage kidney disease ESKD in FSGS will be presented. ASN Kidney Week 2021 is being held virtually November 4-7, 2021. 